Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions.
A more sensitive luminescence immunoassay (LIA) for human papillomavirus type 16 (HPV-16) was developed and used to measure HPV-16 antibodies in cervical samples from 292 college-aged women who were examined at 4-month intervals. Of the 609 collected samples, IgG, IgA, and secretory piece-associated antibodies to HPV-16 were detected in 12%, 6%, and 8%, respectively, of samples tested. Cervical IgG antibodies were most strongly associated with HPV-16 DNA detected within the previous 12 months (odds ratio, 3.3; 95% confidence interval, 1.4-7.8). Secretory IgA (cervical IgA- and secretory piece-positive) was most strongly associated with detection of a squamous intraepithelial lesions 4-8 months earlier (odds ratio, 6.4; 95% confidence interval, 1.9-21.8). As with serum HPV-16 antibodies, there appears to be a several-month delay between cervical HPV infection and detection of cervical antibodies.
Hagensee
M E
ME
Fred Hutchinson Cancer Research Center and Department of Medicine, Louisiana State University, New Orleans, LA 70112, USA. mhagen@lsumc.edu
Koutsky
L A
LA
Lee
S K
SK
Grubert
T
T
Kuypers
J
J
Kiviat
N B
NB
Galloway
D A
DA
D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis*; D002213:Capsid / Q000276:immunology*; D002584:Cervix Uteri / Q000276:immunology*; D004279:DNA, Viral / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007118:Immunoassay; D007071:Immunoglobulin A, Secretory / Q000032:analysis; D008163:Luminescent Measurements; D027383:Papillomaviridae / Q000276:immunology*
D000914:Antibodies, Viral; D004279:DNA, Viral; D007071:Immunoglobulin A, Secretory